CHILDRENS MERCY HOSPITAL
- Type
- Teaching hospital
- Where
- Kansas City, MO
- Medicare CCN
- 263302
- Received
- $3,216,241 in 551 records, 2021 ($202,311 general, $3,013,929 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 19 | $202,311 |
| 2021 | Research payment | 532 | $3,013,929 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 532 | $3,013,929 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 9 | $113,210 |
| Grant | 1 | $60,000 |
| Honoraria | 1 | $24,497 |
| Long term medical supply or device loan | 3 | $2,666 |
| Charitable Contribution | 2 | $1,050 |
| Education | 1 | $699 |
| Food and Beverage | 1 | $184 |
| Debt forgiveness | 1 | $5 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $30,942 | Research payment | In-kind items and services | Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2021 |
| 2021-12-31 | Edwards Lifesciences Corporation | $5,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,524 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2021 |
| 2021-12-31 | PENTAX of America, Inc. | $1,337 | Long term medical supply or device loan | In-kind items and services | VIDEO BRONCHOSCOPE Device, Gastroenterology | 2021 | |
| 2021-12-31 | Linvatec Corporation | $1,261 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2021 | |
| 2021-12-31 | Edwards Lifesciences Corporation | $885 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-31 | AstraZeneca UK Limited | $124 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2021 |
| 2021-12-31 | Aimmune Therapeutics, Inc. | $21 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-12-29 | PFIZER INC. | $7,450 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-20 | Genentech, Inc. | $90 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | AN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS | 2021 |
| 2021-12-17 | Travere Therapeutics, Inc. | $1,120 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2021 | |
| 2021-12-17 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-12-17 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-12-17 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-12-17 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-12-17 | Alexion Pharmaceuticals, Inc. | $690 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-12-16 | Edwards Lifesciences Corporation | $6,630 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-16 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-16 | Edwards Lifesciences Corporation | $1,530 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-16 | Edwards Lifesciences Corporation | $576 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-16 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-16 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-13 | ABBVIE INC. | $3,538 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynam | 2021 |
| 2021-12-13 | Gilead Sciences, Inc. | $120 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2021 |
| 2021-12-10 | Luminex Corporation | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-12-09 | Bio-Rad Laboratories, Inc. | $7,109 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Digital PCR Assays Device, PCR | 2021 | |
| 2021-12-09 | Edwards Lifesciences Corporation | $6,630 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $5,600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $5,460 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $5,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $4,590 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $4,400 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $4,034 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $3,994 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $3,640 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $3,570 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $3,060 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,881 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,800 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,550 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,500 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,275 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,174 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,719 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,530 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,530 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,424 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,422 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,235 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,225 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,225 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $1,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $854 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $688 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $177 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-09 | Edwards Lifesciences Corporation | $88 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2021 |
| 2021-12-08 | PFIZER INC. | $12,359 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-08 | Merck Sharp & Dohme LLC | $9,717 | Research payment | Cash or cash equivalent | Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2021 |
| 2021-12-08 | Incyte Corporation | $42 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $42 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-08 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-12-07 | Organon Llc | $81,596 | Research payment | Cash or cash equivalent | NEXPLANON Drug, CONTRACEPTIVES | Intervention to Facilitate Contraception Provision by Pediatric Hospitalists: A Feasibility Study | 2021 |
| 2021-12-07 | Organon Llc | $67,231 | Research payment | Cash or cash equivalent | NEXPLANON Drug, CONTRACEPTIVES | Impact of basic training contraceptive education and access policy on contraceptive use and childbirth during the first | 2021 |
| 2021-12-07 | BioFire Diagnostics, LLC | $6,637 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2021 |
| 2021-12-07 | Dexcom, Inc. | $5,127 | Research payment | Cash or cash equivalent | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2021 |
| 2021-12-07 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,545 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT440-038_3702_01 | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $5,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $4,500 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $4,080 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $3,060 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $1,728 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $1,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $853 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $600 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $596 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-06 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2021 |
| 2021-12-03 | Boehringer Ingelheim France S.A.S. | $702 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2021 |
| 2021-12-02 | PFIZER INC. | $4,773 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-01 | Novo Nordisk AS | $601 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2021 |
| 2021-12-01 | Travere Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2021 | |
| 2021-12-01 | Travere Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2021 | |
| 2021-12-01 | Boehringer Ingelheim Italia S.p.A. | $13 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2021 |
| 2021-11-29 | Organon Llc | $81,596 | Research payment | Cash or cash equivalent | NEXPLANON Drug, CONTRACEPTIVES | Intervention to Facilitate Contraception Provision by Pediatric Hospitalists: A Feasibility Study | 2021 |
| 2021-11-29 | Organon Llc | $69,239 | Research payment | Cash or cash equivalent | NEXPLANON Drug, CONTRACEPTIVES | A quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con | 2021 |
| 2021-11-29 | Organon Llc | $55,391 | Research payment | Cash or cash equivalent | NEXPLANON Drug, CONTRACEPTIVES | A quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of con | 2021 |
| 2021-11-29 | BioFire Diagnostics, LLC | $2,859 | Research payment | In-kind items and services | FilmArray Device, Clinical Diagnostics | Etiology and Prevalence of Acute Gastroenteritis (AGE) in US Children | 2021 |
| 2021-11-29 | Boehringer Ingelheim France S.A.S. | $702 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2021 |
| 2021-11-25 | PFIZER INC. | $12,879 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-11-17 | Travere Therapeutics, Inc. | $1,229 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2021 | |
| 2021-11-17 | Travere Therapeutics, Inc. | $1,120 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2021 | |
| 2021-11-15 | BioFire Diagnostics, LLC | $5,290 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2021 |
| 2021-11-15 | Genentech, Inc. | $90 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | AN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS | 2021 |
| 2021-11-10 | PFIZER INC. | $8,705 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-11-10 | SANOFI PASTEUR INC. | $450 | Research payment | Cash or cash equivalent | PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine | 2021 | |
| 2021-11-09 | BioFire Diagnostics, LLC | $331 | Research payment | In-kind items and services | SpotFire RST Study | 2021 | |
| 2021-11-07 | Genentech, Inc. | $200 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | AN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS | 2021 |
| 2021-11-07 | Genentech, Inc. | $90 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | AN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS | 2021 |
| 2021-11-05 | Genentech, Inc. | $270 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | AN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS | 2021 |
| 2021-11-03 | Genentech, Inc. | $14,150 | Research payment | Cash or cash equivalent | HEMLIBRA Biological, Hematology | AN OPEN LABEL STUDY TO DETERMINE PK AND PD OF HEMLIBRA IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS | 2021 |
| 2021-11-03 | Allergan, Inc. | $1,200 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin ve | 2021 |
| 2021-11-03 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-03 | Astellas US Technologies | $324 | Research payment | In-kind items and services | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2021 |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $738 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2021 | |
| 2021-11-01 | Travere Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2021 | |
| 2021-11-01 | Travere Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2021 | |
| 2021-11-01 | Boehringer Ingelheim Italia S.p.A. | $13 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2021 |
| 2021-10-29 | VERTEX PHARMACEUTICALS INCORPORATED | $3,277 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i | 2021 | |
| 2021-10-25 | ABBVIE INC. | $700 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynam | 2021 |
| 2021-10-25 | Vero Biotech Inc. | $184 | Food and Beverage | Cash or cash equivalent | Genosyl Drug, Respiratory Therapy | 2021 | |
| 2021-10-24 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Mircera Biological, Hematology | CONFIRMATORY STUDY | 2021 |
| 2021-10-21 | PFIZER INC. | $518 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2021 |
| 2021-10-21 | PFIZER INC. | $422 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2021 |
| 2021-10-21 | PFIZER INC. | $375 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2021 |
| 2021-10-21 | PFIZER INC. | $89 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2021 |
| 2021-10-20 | Gilead Sciences, Inc. | $2,312 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2021 |
| 2021-10-20 | Gilead Sciences, Inc. | $633 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2021 |
| 2021-10-19 | Dexcom, Inc. | $14,972 | Research payment | Cash or cash equivalent | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2021 |
| 2021-10-19 | PFIZER INC. | $700 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-10-18 | PFIZER INC. | $3,296 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2021 |
| 2021-10-18 | Travere Therapeutics, Inc. | $2,556 | Research payment | Cash or cash equivalent | DUET | 2021 | |
| 2021-10-18 | PFIZER INC. | $1,068 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB IBRANCEREGISTERED IN COMBINATION WITH IRINOTECA | 2021 |
| 2021-10-18 | Travere Therapeutics, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUET | 2021 | |
| 2021-10-14 | Aimmune Therapeutics, Inc. | $133 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-10-13 | BioFire Diagnostics, LLC | $4,681 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2021 |
| 2021-10-06 | SANOFI PASTEUR INC. | $1,955 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2021 | |
| 2021-10-06 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,341 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2021 |
| 2021-10-01 | Alexion Pharmaceuticals, Inc. | $60,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-10-01 | BioFire Diagnostics, LLC | $40,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2021 |
| 2021-10-01 | VERTEX PHARMACEUTICALS INCORPORATED | $5,010 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy i | 2021 | |
| 2021-10-01 | Boehringer Ingelheim Italia S.p.A. | $13 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2021 |
| 2021-09-30 | BioFire Diagnostics, LLC | $3,431 | Research payment | In-kind items and services | FilmArray Device, Clinical Diagnostics | Etiology and Prevalence of Acute Gastroenteritis (AGE) in US Children | 2021 |
| 2021-09-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2021 |
| 2021-09-28 | PFIZER INC. | $2,800 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-09-23 | PFIZER INC. | $11,200 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2021 | |
| 2021-09-22 | BioFire Diagnostics, LLC | $8,412 | Research payment | Cash or cash equivalent | SpotFire RST Study | 2021 | |
| 2021-09-22 | BioFire Diagnostics, LLC | $5,174 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2021 |
| 2021-09-21 | PFIZER INC. | $13,029 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-09-20 | Regeneron Pharmaceuticals, Inc. | $13,400 | Research payment | Cash or cash equivalent | EYLEA Biological, OPHTHALMOLOGY | An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity | 2021 |
| 2021-09-16 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2021 | |
| 2021-09-15 | United Therapeutics Corporation | $2,100 | Research payment | Cash or cash equivalent | A SAFETY STUDY OF INTRAVENOUS INFUSION OF BONE MARROW MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES (UNEX-42) IN | 2021 | |
| 2021-09-08 | PFIZER INC. | $52,256 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-09-08 | BioFire Diagnostics, LLC | $300 | Research payment | In-kind items and services | SpotFire RST Study | 2021 | |
| 2021-09-08 | BioFire Diagnostics, LLC | $41 | Research payment | In-kind items and services | SpotFire RST Study | 2021 | |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $175 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $175 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-07 | Aimmune Therapeutics, Inc. | $115 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2021 |
| 2021-09-03 | Luminex Corporation | $7,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-09-01 | JAZZ PHARMACEUTICALS INC. | $133,381 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2021 |
| 2021-09-01 | Boehringer Ingelheim Italia S.p.A. | $13 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2021 |
| 2021-08-30 | Edwards Lifesciences Corporation | $6,364 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
| 2021-08-30 | Edwards Lifesciences Corporation | $3,324 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2021 |
The latest 200 records of 551.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kansas City, MO | County Jackson County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 510,612 | 719,976 | 6,191,814 |
| Population, 2020 census P1 | 508,090 | 717,204 | 6,154,913 |
| Median age B01002 | 35.8 | 37.0 | 39.0 |
| Under 18 B01001 | 22.5% | 23.3% | 22.3% |
| 65 and over B01001 | 14.3% | 15.9% | 17.9% |
| Households B11001 | 221,979 | 306,798 | 2,508,227 |
| Foreign born B05002 | 8.6% | 6.6% | 4.5% |
| Median household income B19013 | $69,166 | $68,577 | $70,702 |
| Median family income B19113 | $92,934 | $90,585 | $91,360 |
| Per capita income B19301 | $41,393 | $39,559 | $39,695 |
| Poverty rate B17001 | 14.6% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.4% | 4.7% | 4.0% |
| Civilian labor force B23025 | 279,828 | 381,433 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.7 | 23.4 | 23.5 |
| Bachelor's degree or higher B15003 | 38.4% | 34.0% | 32.4% |
| Housing units B25001 | 245,346 | 336,288 | 2,825,287 |
| Owner-occupied B25003 | 55.4% | 59.1% | 68.1% |
| Renters B25003 | 44.6% | 40.9% | 31.9% |
| Median home value B25077 | $242,900 | $230,500 | $230,300 |
| Median gross rent B25064 | $1,238 | $1,197 | $1,033 |
| White, not Hispanic B03002 | 54.0% | 59.3% | 76.3% |
| Black B03002 | 25.2% | 22.0% | 10.9% |
| Hispanic or Latino B03002 | 12.5% | 11.4% | 5.2% |
| Asian B03002 | 2.8% | 1.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.
Comments